Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; croscarmellose sodium; lactose monohydrate; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; colloidal anhydrous silica - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; hypromellose; magnesium stearate; macrogol 6000; croscarmellose sodium; titanium dioxide - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 49.605 mg - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 16.535 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; carmellose calcium; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; maize starch - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; maize starch; magnesium stearate; microcrystalline cellulose; iron oxide red - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; indigo carmine aluminium lake; maize starch; hyprolose; magnesium stearate; microcrystalline cellulose - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; microcrystalline cellulose; maize starch; iron oxide yellow; magnesium stearate - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; maize starch; iron oxide red - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.